Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
During Q3 2025, the Bristol Gate US Equity Strategy lagged the S&P 500 benchmark (-0.6% net return vs 8.1% for S&P 500 TR) due to defensive positioning and a lack of exposure to AI-dominated mega-cap tech stocks and value-based sectors. However, the portfolio...
— Achilleas Taxildaris
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Thermo Fisher Scientific Inc.